Find Academic Supervisors

• Bladder Cancer
• Urologic Oncology
• Robot-Assisted Surgery
• +6 more

Knud Fabrin serves as a Clinical Professor in the Department of Urology within the Faculty of Medicine at Aalborg University Hospital. His primary clinical and research focus centers on advanced urologic oncology, particularly bladder cancer management requiring radical cystectomy and innovative surgical techniques. Affiliated with Denmark's national healthcare system, he actively participates in multicenter Nordic collaborations including the NorCys and DaBlaCa trials. His research interests prominently feature Bladder Cancer and Robot-Assisted Surgery , with significant contributions to optimizing neoadjuvant chemotherapy protocols, surgical reconstruction techniques (particularly ileal conduit variations), and postoperative complication management. Current work investigates ctDNA biomarkers for immunotherapy timing and compares retrosigmoid versus conventional urinary diversion methods in robot-assisted cystectomies. Analysis of his 2024 publications reveals strong emphasis on Real-world implementation of evidence-based bladder cancer care Technical refinements in robotic cystectomy Nordic collaborative research frameworks Translational applications of molecular diagnostics His work bridges clinical practice with rigorous trial methodology across Denmark and the Nordic region. Professional activities include participation in the 2012 EAU Robotic Urology Section Congress, demonstrating longstanding engagement with robotic surgical advancements. Current research output shows accelerating contributions to high-impact urologic oncology literature through both journal articles and conference presentations.

Sima PortenView profile

Assistant Professor

• Urologic Oncology
• Genitourinary Cancer
• Bladder Cancer
• +7 more

Dr. Sima Porten is a specialist in genitourinary cancers and a faculty member in the Department of Urology at the University of California San Francisco (UCSF) School of Medicine. She is part of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center, where she focuses on the diagnosis and treatment of bladder, kidney, and high-risk prostate cancers. Her research is centered on the biological and genetic mechanisms of urothelial carcinoma, aiming to develop personalized diagnostic tools and therapies. She has published extensively on topics including urine biomarkers, molecular imaging, health disparities, and treatment outcomes in bladder cancer. Her work integrates clinical practice, translational research, and health services to improve patient care. Dr. Porten’s recent publications reveal a strong focus on non-invasive diagnostics, molecular profiling, equity in cancer care, and innovative clinical trial design. Her research spans immunology, genetics, imaging, and patient-reported outcomes, reflecting a multidisciplinary approach to advancing bladder cancer management. Howard Hughes Medical Institute Research Scholar, NIH (2003) Alpha Omega Alpha Honor Society (2006) Julius R. Krevans Award for Clinical Excellence (2012) John Quale Travel Fellowship (2015) William R. Smart Distinguished Teaching Award (2017) Best Reviewer Award, Journal of Urology (2017) New Investigator Scholarship-Leadership Award, ALLIANCE Foundation (2019) Muriel Steele Society Honor (UCSF) Dr. Porten has been involved in major multi-institutional research collaborations and clinical trials, including SWOG S1605 and ECOG-ACRIN EA8212, contributing to national efforts in standardizing care and evaluating novel therapies. She has received grant support through awards such as the Faculty Learning and Development Fund and the ALLIANCE Foundation. While no direct mention of advising students is made, her leadership in research and teaching suggests a mentorship role within the department. She is actively engaged in professional societies including the American Urological Association and the Society of Urologic Oncology. Dr. Porten is affiliated with the UCSF Department of Urology and the Helen Diller Family Comprehensive Cancer Center, where she contributes to a multidisciplinary team advancing research and clinical care in urologic oncology.

Vadim KoshkinView profile

Physician Scientist

• Genitourinary Medical Oncology
• Translational Research
• Clinical Trials
• +7 more

Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco (UCSF) , specializing in bladder, prostate, kidney, and testicular cancers. His work focuses on clinical and translational research, particularly the design of clinical trials and the discovery of biomarkers and treatment targets for genitourinary malignancies. Education : BA in Cognitive Science (University of Pennsylvania, 2007), MD (University of Chicago, 2012), Intern and Resident in Internal Medicine (University of Michigan Health System, 2013-2015), Fellow in Hematology-Oncology (Cleveland Clinic, 2018). His research spans multiple areas in genitourinary oncology, including immunotherapy (e.g., checkpoint inhibitors, combination therapies), biomarker discovery (e.g., DLL3, HSD3B1 variants), and clinical trial design for cisplatin-ineligible patients, neoadjuvant therapies, and treatment sequencing. Key themes include improving outcomes for advanced bladder and prostate cancers through precision medicine and translational studies. The 15 most recent publications highlight his expertise in urothelial and prostate cancer research , with recurring focus on immune checkpoint inhibitors , biomarker validation , and clinical trial outcomes . His work addresses challenges in renal function adaptation, non-clear cell renal cancer, and small-cell bladder cancer. Scientific Awards : Junior Clinical Investigator Award (Helen Diller Family Comprehensive Cancer Center, 2019) John Quale Travel Fellowship (BCAN Bladder Cancer Think Tank, 2017) Young Investigator Abstract Award (International Kidney Cancer Symposium, 2017) Conquer Cancer Foundation Merit Award (ASCO 2017) Keith Edson Scholarship (2009) As a Principal Investigator for the Prostate Cancer Foundation-funded study on CDK4/6 inhibition and PSMA-targeted radioligand therapy (2021-2024), he drives innovative research. While no specific lab or team details are provided, his collaborations with institutions like Cleveland Clinic, University of Michigan, and UCSF underscore his multidisciplinary approach.

Jonathan Eric RosenbergView profile

Clinical Professor

• Genitourinary Oncology
• Bladder Cancer
• Molecular Subtypes
• +3 more

Jonathan Eric Rosenberg is a Clinical Professor in the Department of Medicine at Memorial Sloan Kettering Cancer Center , specializing in Genitourinary Oncology . His research focuses on molecular subtypes in bladder cancer, DNA damage response, and clinical trial outcomes.

• Molecular Biology
• Toxicology
• Cancer Research
• +3 more

Volkan M Gurel is an Adjunct Assistant Professor of Pathology and Laboratory Medicine at Brown University. He holds a PhD in Biochemistry from West Virginia University (2004) and has conducted extensive research in molecular biology, toxicology, and cancer-related gene expression mechanisms. Education: PhD, West Virginia University (2004) MS, University of California, Davis (1998) BS, Ankara University (1994) His research focuses on heavy metal-induced carcinogenesis, neurotransmitter-based therapies for urological disorders, and molecular mechanisms of DNA repair and cellular stress response. He has also explored the role of metallothionein isoforms in cancer progression and chemoresistance. Key research domains include environmental toxicology , oncology , molecular pathogenesis , and pharmacology . Recent publications emphasize gene-environment interactions, bacterial resistance mechanisms, and therapeutic applications of neurotransmitters. Dr. Gurel has contributed to courses like Environmental Health & Disease 1820 , covering dose-response relationships, toxicant metabolism, and case studies on environmental health impacts.

• Molecular Biology
• Genetics
• Cancer Research
• +6 more

Dr. Gregory Yochum is an Associate Professor at Penn State University, affiliated with both the College of Medicine's Department of Molecular and Precision Medicine and Department of Surgery. His research focuses on the molecular mechanisms of Wnt/β-catenin signaling in intestinal homeostasis, inflammatory bowel disease (IBD), and colorectal cancer (CRC), with a specific emphasis on MYC proto-oncogene regulation through chromatin architecture modifications and long-range DNA loops. BS, Bucknell University (1990-1994) PhD, University of Utah (1996-2002) Postdoctoral Fellowship, Vollum Institute for Advanced Biomedical Research (2002-2009) Current projects investigate how TCF/β-catenin complexes modulate target gene expression, alongside the role of RNA-binding protein TTP in intestinal barrier function and its implications for ulcerative colitis (UC) and CRC. Collaborations with Dr. Walter Koltun's lab utilize a biobank of 4,500+ patients to explore genetic and environmental factors (e.g., microbiome) in intestinal disease. His work contributes to UN Sustainable Development Goals through advancements in medical research and education. Key research outputs include studies on: BRD4 inhibition for IBD therapy Epigenetic alterations in pediatric IBD Metabolic reprogramming in CRC metastasis Interferon signaling in bladder cancer Microbial consortia in diverticulitis His lab employs biochemical approaches in CRC cell lines, mouse models, and human tissues to validate findings.

• Urology
• Bladder Cancer
• Prostate Cancer
• +7 more

Ettore De Berardinis is an Associate Professor in the Department of Maternal Infantile and Urological Sciences at Sapienza University of Rome. He teaches Integrated Pathology II - Urology and Integrated Medical-Scientific Methodology courses for Medicine and Surgery students in their fourth year. His research focuses on urological oncology with particular emphasis on bladder cancer diagnostics and treatment. Dr. De Berardinis has pioneered work on the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer staging and has conducted extensive research on biomarkers for predicting Bacillus Calmette-Guérin (BCG) therapy response in non-muscle invasive bladder cancer. His methodology frequently involves analysis of US insurance claims data to evaluate perioperative outcomes and healthcare costs across various urological procedures. Recent publications reveal a strategic shift toward evidence-based analysis of surgical techniques, particularly robotic-assisted radical prostatectomy configurations and minimally invasive approaches for lower urinary tract symptoms. His 2023-2025 work demonstrates increasing sophistication in biomarker research, with studies on extracellular vesicles and NGS multigene panels for risk stratification in bladder cancer. Dr. De Berardinis leads two significant research initiatives: one examining the interplay between intravesical BCG and PD-L1 expression in non-muscle invasive bladder cancer, and another investigating oncogenic aberrations as predictive biomarkers for BCG efficacy. His collaborative approach is evident through multi-institutional studies involving US healthcare data and international research teams.

David OhView profile

Associate Professor

• Immunotherapy
• Cancer Immunotherapy
• Genitourinary Malignancies
• +5 more

David Oh, MD, PhD is an Associate Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He is a physician-scientist specializing in cancer immunotherapy with particular expertise in genitourinary malignancies, including prostate and bladder cancers. Dr. Oh sees patients in the Cancer Immunotherapy Program at UCSF and leads numerous early-phase clinical trials focused on adoptive cell therapies for solid tumors, including CAR-T and TCR therapies. His laboratory conducts translational research on cytotoxic immune effectors in anti-tumor responses and immune-related adverse events following immunotherapy. Harvard College AB 2000 Biochemical Sciences Stanford University School of Medicine MD/PhD 2011 Medicine, Physiology University of California, San Francisco Residency 2014 Internal Medicine University of California, San Francisco Fellowship 2017 Hematology/Oncology Dr. Oh's research focuses on developing novel immunotherapies with enhanced activity and reduced toxicity for patients with solid cancers. His work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems. Recent publications highlight his expertise in CD4+ T cell function in antitumor immunity, immune-related adverse events, and predictive biomarkers for immunotherapy response. His research has shown particular promise in understanding the role of cytotoxic CD4+ lymphocytes in bladder cancer and developing strategies to manage immune checkpoint inhibitor colitis. Analysis of Dr. Oh's recent publications reveals a strong focus on translational immunology with emphasis on T cell responses to cancer therapies. His work consistently bridges basic science and clinical applications, particularly in the areas of immune monitoring, biomarker development, and management of immunotherapy toxicities. The publications show increasing sophistication in analytical approaches, moving from traditional immunological techniques to advanced single-cell and spatial multi-omics methods. University of California, San Francisco Clinical Fellow Award 2015 Conquer Cancer Foundation of American Society of Clinical Oncology Merit Award 2016 Conquer Cancer Foundation Young Investigator Award 2017 Bladder Cancer Advocacy Network Young Investigator Award 2018 Prostate Cancer Foundation Young Investigator Award 2018 Damon Runyon Cancer Research Foundation Clinical Investigator Award 2021 Dr. Oh leads the NIH-funded project 'Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events' (K08AI139375). His clinical trials portfolio includes studies of adoptive cell therapies, intratumoral immunotherapies, and next-generation cytokine therapies for solid tumors. He has mentored numerous trainees in the field of cancer immunology and regularly collaborates with researchers across multiple disciplines including immunology, urology, and gastroenterology. His laboratory maintains strong connections with clinical programs at UCSF, facilitating rapid translation of research findings into patient care.

• Urologic Oncology
• Bladder Cancer
• Clinical Trials
• +5 more

Piyush Agarwal is a Professor in the Department of Surgery-Urology at the University of Chicago, specializing in urologic oncology with a focus on bladder cancer and genitourinary malignancies. He maintains an active research program centered on clinical trials, surgical outcomes, and therapeutic innovations in urologic cancers. Dr. Agarwal's research focuses on multiple aspects of urologic oncology, including clinical trial design for bladder cancer therapies, surgical techniques for radical cystectomy, organ preservation strategies, and biomarker development. His work spans translational research with particular emphasis on targeted therapies and immunotherapies for advanced genitourinary tumors. He maintains collaborative relationships across multiple institutions for clinical trial consortia and has contributed to standardization of treatment protocols in urologic oncology. Dr. Agarwal has an extensive publication record with recent articles demonstrating trends in immunotherapy clinical trials (particularly checkpoint inhibitors and combination therapies), surgical innovations in cystectomy techniques, and biomarker-driven treatment approaches. His work frequently addresses both clinical outcomes and methodological improvements in clinical trial design for urologic malignancies. As an active clinical investigator, Dr. Agarwal contributes to multicenter trials through leadership roles and participates in expert consensus panels developing best practice guidelines for urologic cancer management and tissue procurement standards in oncology research.

Stuthi PerimbetiView profile

Assistant Professor

• Malignant Neoplasm
• Breast Cancer
• Prostate Cancer
• +7 more

Stuthi Perimbeti is an Assistant Professor at the Penn State Cancer Institute , affiliated with the Department of Medicine in the College of Medicine at Penn State University. Her research focuses on cancer-related health disparities, molecular targets in disease therapy, and clinical outcomes in oncology. Key Research Areas : Breast Cancer, Prostate Cancer, Lung Cancer, Racial Disparities, Medicaid Expansion, Molecular Targets Her recent publications highlight trends in oncology and public health , including studies on patient preferences in non-small-cell lung cancer, psychological distress in prostate cancer survivors, and policy impacts on bladder cancer treatment. She contributes to the United Nations Sustainable Development Goals (SDGs) by addressing health equity and disease therapy. Collaborations : Work with researchers like Jiang, Joshi, and Chatta Geographic Focus : United States, with emphasis on clinical outcomes and health policy

Fredrik LiedbergView profile

Professor

• Urothelial Carcinoma
• Bladder Cancer
• Surgical Oncology
• +4 more

Fredrik Liedberg is Professor at Lund University's Department of Urology (Malmö) and Principal Investigator at Lund University Cancer Centre (LUCC). He leads the translational research group 'Clinical and experimental urothelial carcinoma research' focusing on improving prognostication, developing biomarkers, and optimizing surgical outcomes for bladder and upper urinary tract cancers. His research spans: Molecular subtyping of urothelial carcinomas Neoadjuvant chemotherapy responses Surgical complication prevention Lymph node metastasis mapping Diagnostic pathway optimization Contributing to UN Sustainable Development Goals through cancer research. Research trends show strong focus on precision oncology approaches across 213 publications, with recent work (2020-2025) emphasizing molecular classification, surgical outcomes, and population-level diagnostic patterns in urological cancers. Currently leads multiple projects: Precision medicine for non-muscle invasive bladder cancer (Sjöbergstiftelsen funded, 2025-2028) Clinical translation of molecular subtypes (Swedish Research Council, 2021-2025) Manages the urothelial carcinoma research team at LUCC and regularly organizes academic conferences including the UroCAN Retreat and Malmö Cancer Seminars.

Ines AmbiteView profile

Researcher

• Urinary Tract Infections
• Cancer Immunotherapy
• Transcriptional Regulation
• +7 more

Ines Ambite is an Associate Researcher at the Division of Microbiology, Immunology and Glycobiology (MIG) and Medical Microbiology at Lund University, with affiliations to Infect@LU. Her work bridges urinary tract infections and cancer treatment response , focusing on transcriptional control mechanisms through translational molecular research. Key affiliations: Division of MIG, Medical Microbiology, Infect@LU Email: ines.ambite@med.lu.se Research emphasizes immunomodulatory therapies for infection and oncology, leveraging proteomics and molecular pathways. Recent publications highlight: ER remodeling in tumor cells Innate/adaptive immune imbalance in pyelonephritis Multitarget inhibition of MYC by bacterial proteases Alpha1-oleate clinical trials in bladder cancer Comparative analyses of immunotherapies Her work aligns with UN Sustainable Development Goals for global health advancement.

Divya ParikhView profile

Assistant Clinical Professor

• Medical Oncology
• Genitourinary Cancers
• Financial Toxicity
• +8 more

Dr. Divya Parikh is a Clinical Assistant Professor in the Department of Medicine - Oncology at Stanford School of Medicine. She specializes in treating genitourinary cancers and is actively involved in clinical practice, education, and research aimed at improving patient outcomes. Boston University School of Medicine, MD (2015) Stanford University, Internal Medicine Residency (2018) Stanford University, Hematology and Oncology Fellowship (2021) Stanford University, Master of Science in Health Policy (2021) Dr. Parikh's research focuses on medical oncology, particularly genitourinary cancers. Her work addresses financial toxicity, advance care planning, healthcare disparities, and cost-effectiveness of cancer treatments. She utilizes interdisciplinary approaches involving social work, machine learning, and quality improvement frameworks. Her recent publications highlight interventions to reduce financial burden in urologic cancer patients, applications of computer models in advance care planning, and cost comparisons of bladder cancer treatments. These studies reflect her commitment to optimizing patient care through clinical research and policy analysis. Dr. Parikh mentors medical residents and fellows, emphasizing compassionate and evidence-based oncological care. She is affiliated with Stanford Health Care and the VA Palo Alto Health Care System, where she provides clinical services.

William Y. KimView profile

Professor

• Cancer Genetics
• Genitourinary Oncology
• Immunotherapy
• +3 more

William Y. Kim, MD , is a Professor of Medicine and Genetics at the UNC School of Medicine , where he serves as the Rush S. Dickson Distinguished Professor . He leads the Kim Laboratory at the UNC Lineberger Comprehensive Cancer Center , focusing on the genetics and biology of bladder and kidney cancers . Kim is also Co-Leader of the UNC Lineberger Cancer Genetics Research Program and Co-Director of the Mouse Phase 1 Unit. Medical School: Brown University (1996) Certification: Internal Medicine-Medical Oncology (2002) His research integrates genomics and cancer biology to identify therapeutic vulnerabilities in renal cell carcinoma (RCC) and bladder cancer . Key projects include studying NRF2 transcription factor , KDM6A , and FGFR3 in bladder cancer progression, and investigating non-canonical tumor antigens in RCC. The lab employs patient-derived xenografts , genetically engineered murine models , and single-cell RNA sequencing to dissect tumor-immune interactions and improve immune checkpoint blockade outcomes. Recent publications highlight his work on bladder cancer subtypes , immunotherapy combinations , and renal carcinoma genetics . His awards include the BCAN Innovation Award (2014), ASCI membership (2014), and grants from the American Association for Cancer Research (2012) and DOD Prostate Cancer Program (2008, 2010). Kim also contributes to clinical trials and collaborates with industry partners like GeneCentric Therapeutics . Scientific Awards: Rush S. Dickson Distinguished Professor (2015) Bladder Cancer Advocacy Network Innovation Award (2014) ASCI member (2014) AACR-Kure It Grant (2012) Kim's lab emphasizes team science and multidisciplinary collaboration , particularly with the UNC Vincent Lab. Current initiatives explore cancer-associated fibroblasts (CAFs) and their role in immunotherapy resistance, alongside non-canonical tumor antigens in RCC. His clinical work centers on genitourinary malignancies , bridging translational research with patient care.

Philip A. SuteraView profile

Assistant Professor

• Radiation Oncology
• Prostate Cancer
• Bladder Cancer
• +7 more

Philip A. Sutera, M.D., is an Assistant Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices at the Wilmot Cancer Institute and is affiliated with the University of Rochester Medical Faculty Group (URMFG) and Accountable Health Partners (AHP). His clinical and research focus spans advanced radiation therapies for prostate and bladder cancer, with particular emphasis on oligometastatic disease and genomic biomarkers. MD, University of Pittsburgh School of Medicine (2019) Residency, Radiation Oncology, Johns Hopkins University School of Medicine (2020-2024) Internship, Internal Medicine, Allegheny General Hospital (2019-2020) Dr. Sutera's research integrates machine learning, radiomics, and genomic profiling to optimize radiation therapy outcomes. His work has been published in leading journals like Radiotherapy and Oncology and Clinical Cancer Research , with a focus on PSMA PET imaging, metastasis-free survival prediction, and pathway-based biomarkers in castration-sensitive prostate cancer. His recent publications highlight trends in artificial intelligence applications for prognostic modeling, genomic determinants of therapy response, and comparative analyses of imaging modalities (PSMA PET/CT vs conventional imaging) in oligometastatic disease. Recurring themes include stereotactic ablative radiotherapy (SABR), immune cell infiltration in chemoradiation, and mitochondrial dysfunction in radiation-induced apoptosis. ASTRO Annual Meeting Abstract Award (2024) ASCO Conquer Cancer Merit Award (2024) American Radium Society Travel Grant (2023) Bert and Sally O'Malley Award (2019) ... Dr. Sutera's clinical work involves stereotactic body radiation therapy (SBRT) for pancreatic carcinoma and salvage radiosurgery for recurrent gliomas. His research extends to DNA damage mechanisms in radiation therapy and proteomic responses to novel agents like Dinaciclib and YM155. He collaborates with teams in the STOMP and ORIOLE trials and contributes to evolving definitions of disease burden in metastatic castration-sensitive prostate cancer.